Precigen Signs Up to $125 Million Credit Facility
with Pharmakon Advisors
08:02 AM EDT, 09/03/2025 (MT Newswires) -- Precigen (PGEN) said Wednesday that it has signed a two-tranche credit facility deal of up to $125 million with investment funds managed by Pharmakon Advisors.
The first tranche of $100 million was financed at closing, while the second tranche of $25 million can be drawn by Precigen through March 31, 2027, the biopharmaceutical company said.
The $100 million tranche will support US commercialization of Papzimeos immunotherapy to treat recurrent respiratory papillomatosis in adults, the company said.
Precigen said the credit facility would mature on the fifth anniversary of the first tranche's closing date.
Shares of Precigen were up more than 3% in recent Wednesday premarket activity.
Market Data 
Markets 
AI
